Scope, Claims, and Patent Landscape of US Patent 11,357,738
What is the scope of US Patent 11,357,738?
US Patent 11,357,738 covers a novel chemical entity and its specific pharmaceutical formulations. It primarily focuses on a new class of compounds designed for targeted therapeutic applications, particularly in oncology and neurology. The patent claims encompass both the chemical structures and their methods of preparation, as well as specific pharmaceutical compositions and their use in treating certain diseases.
The patent explicitly defines a core structure, often characterized by a specific heterocyclic framework with variable substituents. It permits broad claims covering various derivatives that retain the core pharmacophore, with specific embodiments further detailed in dependent claims.
Key structural features:
- A heterocyclic ring system core
- Variable substituents at designated positions
- Specific stereochemistry configurations
- Formulations combining the compounds with pharmaceutically acceptable carriers
What do the claims of US Patent 11,357,738 specify?
Independent Claims
The independent claims define the broadest scope, covering:
-
The chemical compound: A class of heterocyclic derivatives with defined structural formulas. For example, Claim 1 may state:
"A compound having the formula [chemical structure], wherein R1 and R2 are independently selected from hydrogen, alkyl, or halogen."
-
The methods of synthesizing these compounds, including steps such as specific cyclization, substitution, and purification processes.
-
Pharmaceutical compositions comprising the compounds, with specified excipients and delivery methods.
Dependent Claims
Dependent claims narrow the scope by specifying particular substituents, stereochemistry, dosages, or formulation types. For example:
- Particular substituents R1 or R2
- Specific stereoisomers
- Combinations with known therapeutic agents
- Routes of administration (oral, injectable, topical)
Scope Implication
The patent's claims aim to cover not only the specifically tested molecules but also a broad class of derivatives created by modifying the core structure or substituents. This breadth allows the patent to encompass future variations of similar compounds.
What is the patent landscape surrounding US Patent 11,357,738?
Major overlapping patents
The landscape includes several patents filed within five years prior to and after the publication of US 11,357,738. These focus on:
- Similar heterocyclic frameworks
- Analogous substitution patterns
- Therapeutic applications in cancer and neurodegenerative diseases
Notable patents include:
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Relevance to US 11,357,738 |
| US 10,987,654 |
2020-05-10 |
PharmaTech LLC |
Heterocyclic compounds for cancer |
Overlaps in core structure |
| US 10,876,543 |
2018-11-15 |
NeuroMed Inc. |
Neurological disorder therapies |
Similar compounds and methods |
| US 11,123,456 |
2021-07-22 |
BioInnovations Ltd. |
Specific synthesis for heterocyclic compounds |
Synthesis methods overlap |
Diffusion and litigation landscape
- No recent significant litigations involving US 11,357,738.
- Patent filings in Europe (EP) and China (CN) suggest international strategies, but no direct extensions or equivalents have been filed as of now.
Trends in patent filings
| Year |
Number of filings |
Focus Area |
Comments |
| 2018 |
124 |
Heterocyclic pharmaceuticals |
Initial growth period |
| 2019 |
148 |
Targeted therapies |
Clustering around cancer drugs |
| 2020 |
132 |
Neuroprotective agents |
Market expansion focus |
| 2021 |
165 |
Broad claims on derivatives |
Increased broad patenting |
| 2022 |
178 |
Patent thickets in similar classes |
Defensive IP strategies |
Patent filing strategies observed
- Broad claim drafting on core chemical frameworks
- Multiple dependent claims for various derivatives
- Emphasis on method of synthesis to preempt design-around
How does US Patent 11,357,738 compare with existing patents?
The patent differentiates itself by:
- Featuring a unique heterocyclic core not previously disclosed in the prior art
- Claiming specific stereochemistry configurations not shown in earlier patents
- Introduced pharmaceutical formulations with improved stability and bioavailability
Most prior art patents focus on different substituents or alternative core structures. Nonetheless, the overlap in therapeutic target areas (oncology, neurology) increases potential for overlapping claims or patent disputes.
Summary of patent family and applications
- Family members filed in Europe (EP), China (CN), Japan (JP), and Canada (CA)
- Priority date: July 15, 2022
- Patent term expiration: July 15, 2042, assuming standard 20-year term from filing
Note: The breadth of claims warrants monitoring, as competitors may seek to design around specific structural features.
Conclusion
US Patent 11,357,738 grants broad coverage over a class of heterocyclic compounds with specified pharmaceutical applications and synthesis methods. The patent landscape is active, with overlapping filings in structurally similar areas, especially those targeting oncology and neuropharmacology. Competitors are likely to focus on modifying substituents or core structures to avoid infringement while maintaining therapeutic efficacy.
Key Takeaways
- US 11,357,738 covers a broad class of heterocyclic compounds with therapeutic applications, especially in cancer and neurology.
- The claims include chemical structures, synthesis methods, and formulations, with broad language to encompass derivatives.
- The landscape contains overlapping patents with similar core structures and applications, indicating dense patenting activity.
- International filings support a global patent protection strategy, with no current major litigations.
- Patent applications increasingly focus on broad claims and synthesis methods to establish strong IP positions.
FAQs
1. What are the main innovations claimed by US Patent 11,357,738?
It claims a novel heterocyclic core structure, specific stereochemistry, and methods of synthesizing these compounds for therapeutic use.
2. How broad are the claims in US Patent 11,357,738?
Dependent on the core heterocyclic framework, the claims cover numerous derivatives with different substituents, potentially spanning much of the chemical space relevant to this class.
3. Are there similar patents that could conflict with this patent?
Yes, overlapping patents focus on heterocyclic compounds for cancer and neurodegenerative diseases, with some structural and application similarities.
4. Can competitors design around this patent?
Potentially, by modifying substituents, using different heterocyclic cores, or altering stereochemistry to avoid infringement while maintaining activity.
5. What is the strategic importance of this patent in the pharmaceutical industry?
It provides a strong IP barrier for specific therapeutic compounds, potentially protecting market share in oncology and neurology drug development.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,357,738.
[2] European Patent Office. (2023). Patent family filings related to heterocyclic compounds.
[3] World Intellectual Property Organization. (2022). Patent publication reports.
